Search Results (1 to 10 of 118 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 23 Journal of Medical Internet Research
- 22 JMIR Research Protocols
- 15 JMIR Formative Research
- 15 JMIR mHealth and uHealth
- 7 JMIR Medical Informatics
- 5 JMIR Public Health and Surveillance
- 4 JMIR Medical Education
- 4 Online Journal of Public Health Informatics
- 3 Interactive Journal of Medical Research
- 3 JMIR Human Factors
- 3 JMIR Mental Health
- 3 JMIR Rehabilitation and Assistive Technologies
- 3 JMIR Serious Games
- 2 JMIRx Med
- 2 Journal of Participatory Medicine
- 1 JMIR Aging
- 1 JMIR Cardio
- 1 JMIR Pediatrics and Parenting
- 1 JMIR Perioperative Medicine
- 0 Medicine 2.0
- 0 iProceedings
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Dermatology
- 0 JMIR Nursing
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 JMIR XR and Spatial Computing (JMXR)
At the national level, the German Medical Informatics Initiative (MII) is a federal effort dedicated to digitizing the German health care system. As a part of this initiative, a medication task force group has been established to leverage standardized frameworks for different medication processes [30]. In addition, the gematik [31] is the current organization responsible for the federal telematics infrastructure (TI), a central platform for digital applications.
JMIR Med Inform 2025;13:e64099
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Measuring Mental Health in 2 Brazilian University Centers: Protocol for a Cohort Survey
JMIR Res Protoc 2025;14:e63636
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
The physician acceptance of biosimilars for inflammatory diseases is still at stake, with a vast majority of US physicians, including rheumatologists, dermatologists, and gastroenterologists, not willing to switch stable patients to a biosimilar [16], over 95% of German rheumatologists preferring to prescribe an originator biologic rather than a biosimilar as first- or second-line therapy if unrestricted [17], and French rheumatologists being favorable toward the implementation of biosimilars, but very few actually
JMIR Form Res 2024;8:e56553
Download Citation: END BibTex RIS